{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:18:45Z","timestamp":1791591525378,"version":"4.3.4"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Clinical practice currently faces a significant shortfall in specific biomarkers needed for diagnosing right ventricular (RV) remodeling in patients with pulmonary hypertension (PH). While small noncoding microRNAs (miRNAs) are crucial regulators of RV remodeling, the biomarker potential of serum miRNAs in this process is little known. This study systematically screened and identified candidate serum miRNAs as potential diagnostic biomarkers for RV remodeling in PH patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Pulmonary artery banding (PAB) was performed in Sprague-Dawley (SD) rats and RV modeling was measured by echocardiographic and histological analyses 4 weeks after surgery. High-throughput miRNA sequencing of serum samples was performed to profile differentially-expressed miRNAs (dif-miRNAs) and preliminarily screen candidate miRNAs. The diagnostic power of the candidate miRNA was further validated in 100 patients [20 with adaptive RV pressure overload; 20 with maladaptive RV pressure overload; 20 with left heart failure (LHF); 19 with left ventricular hypertrophy and 21 controls].<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>PAB rats exhibited severe RV hypertrophy, fibrosis and enlargement of RV cardiomyocytes compared with sham group. MiRNA sequencing analyses revealed 19 dif-miRNAs (12 upregulated and 7 downregulated) between the two groups. Among the 12 upregulated miRNAs, miRNA-486 exhibited highest elevation in PAB group and was supposed to be the candidate biomarker for RV modeling. Serum miRNA-486 levels were lower in control and left ventricular hypertrophy (LVH) patients compared to PH patients, and significantly higher in maladapted RV patients than in adapted RV patients. Serum miRNA-486 was significantly higher in LHF patients compared to controls, but still significantly lower than in PH patients. In receiver operating characteristic (ROC) analysis, serum miRNA-486 was a good predictor of RV maladaptation in PH patients (cut-off value 3.441, AUC 0.8625), which was not significantly different from B-type natriuretic peptide (BNP). Elevated serum miRNA-486 levels (\u22653.441) were associated with reduced TAPSE\/PASP ratios and increased BNP levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Serum miRNA-486 has the potential to be a valuable noninvasive biomarker for diagnosing RV remodeling in patients with PH.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1518022","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T06:57:50Z","timestamp":1738133870000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Circulating miRNA-486 as a novel diagnostic biomarker for right ventricular remodeling"],"prefix":"10.3389","volume":"12","author":[{"given":"Huiling","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuchuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuenan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1183\/09031936.00148310","article-title":"Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension","volume":"38","author":"Campo","year":"2011","journal-title":"Eur Respir J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1016\/j.jacc.2011.06.068","article-title":"Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy","volume":"58","author":"van de Veerdonk","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1161\/CIRCULATIONAHA.120.047626","article-title":"Identification of long noncoding RNA H19 as a new biomarker and therapeutic target in right ventricular failure in pulmonary arterial hypertension","volume":"142","author":"Omura","year":"2020","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrcardio.2013.12","article-title":"Assessment and treatment of right ventricular failure","volume":"10","author":"Simon","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/eurheartj\/ehaa037","article-title":"Aetiology and outcomes of severe right ventricular dysfunction","volume":"41","author":"Padang","year":"2020","journal-title":"Eur Heart J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2003957","DOI":"10.1183\/13993003.03957-2020","article-title":"Endothelial cells in the pathogenesis of pulmonary arterial hypertension","volume":"58","author":"Evans","year":"2021","journal-title":"Eur Respir J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S0735-1097(97)00452-X","article-title":"Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension","volume":"31","author":"Nagaya","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.110.979500","article-title":"Natriuretic peptide testing in heart failure","volume":"123","author":"Kim","year":"2011","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ebiom.2016.02.038","article-title":"Circulating cancer biomarkers: the macro-revolution of the micro-RNA","volume":"5","author":"Montani","year":"2016","journal-title":"EBioMedicine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/CIRCRESAHA.108.192872","article-title":"MicroRNA regulation of cardiovascular development","volume":"104","author":"Cordes","year":"2009","journal-title":"Circ Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jjcc.2019.05.018","article-title":"MicroRNAs: emerging biomarkers for atrial fibrillation","volume":"74","author":"Komal","year":"2019","journal-title":"J Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"738","DOI":"10.5935\/abc.20180215","article-title":"Role of miRNAs on the pathophysiology of cardiovascular diseases","volume":"111","author":"Silva","year":"2018","journal-title":"Arq Bras Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/FJC.0000000000000178","article-title":"MicroRNA signature and cardiovascular dysfunction","volume":"65","author":"Arunachalam","year":"2015","journal-title":"J Cardiovasc Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1161\/CIRCRESAHA.111.247452","article-title":"Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?","volume":"110","author":"Creemers","year":"2012","journal-title":"Circ Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"888948","DOI":"10.3389\/fendo.2022.888948","article-title":"Serum miRNA profile in diabetic patients with ischemic heart disease as a promising non-invasive biomarker","volume":"13","author":"Bielska","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/ijms21020561","article-title":"Challenges in using circulating micro-RNAs as biomarkers for cardiovascular diseases","volume":"21","author":"Felekkis","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3390\/biomedicines8100430","article-title":"Sex-Dependent changes in right ventricular gene expression in response to pressure overload in a rat model of pulmonary trunk banding","volume":"8","author":"Labazi","year":"2020","journal-title":"Biomedicines"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e002636","DOI":"10.1161\/CIRCHEARTFAILURE.115.002636","article-title":"Right ventricular myocardial stiffness in experimental pulmonary arterial hypertension","volume":"9","author":"Rain","year":"2016","journal-title":"Circ Heart Fail"},{"key":"B19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B20","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1183\/16000617.0062-2015","article-title":"Right heart catheterisation: best practice and pitfalls in pulmonary hypertension","volume":"24","author":"Rosenkranz","year":"2015","journal-title":"Eur Respir Rev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1101\/gr.082701.108","article-title":"Most mammalian mRNAs are conserved targets of microRNAs","volume":"19","author":"Friedman","year":"2009","journal-title":"Genome Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41576-023-00611-y","article-title":"microRNAs in action: biogenesis, function and regulation","volume":"24","author":"Shang","year":"2023","journal-title":"Nature Reviews. Genetics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0001523","DOI":"10.1128\/cmr.00015-23","article-title":"MicroRNAs in infectious diseases: potential diagnostic biomarkers and therapeutic targets","volume":"36","author":"Kimura","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"B24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1146\/annurev-pathmechdis-012418-012827","article-title":"Opportunities for microRNAs in the crowded field of cardiovascular biomarkers","volume":"14","author":"Halushka","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/ejhf.332","article-title":"Signature of circulating microRNAs in patients with acute heart failure","volume":"18","author":"Ovchinnikova","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1007\/s00392-023-02162-y","article-title":"Fibroblast growth factor 23 as a biomarker of right ventricular dysfunction in pulmonary hypertension","volume":"112","author":"Widmann","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2217\/bmm-2022-0395","article-title":"GDF-15 and soluble ST2 as biomarkers of right ventricular dysfunction in pulmonary hypertension","volume":"16","author":"Keranov","year":"2022","journal-title":"Biomark Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1093\/cvr\/cvx153","article-title":"MicroRNAs in right ventricular remodelling","volume":"113","author":"Batkai","year":"2017","journal-title":"Cardiovasc Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.athoracsur.2007.04.006","article-title":"Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension","volume":"84","author":"Reesink","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"B30","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s00018-022-04406-y","article-title":"miRNA-486-5p: signaling targets and role in non-malignant disease","volume":"79","author":"Douvris","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1073\/pnas.1000300107","article-title":"Regulation of PI3-kinase\/akt signaling by muscle-enriched microRNA-486","volume":"107","author":"Small","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B32","doi-asserted-by":"publisher","first-page":"17016","DOI":"10.1073\/pnas.0708115104","article-title":"Distinctive patterns of microRNA expression in primary muscular disorders","volume":"104","author":"Eisenberg","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ncrna.2020.01.001","article-title":"MicroRNA-486-5p and microRNA-486-3p: multifaceted pleiotropic mediators in oncological and non-oncological conditions","volume":"5","author":"ElKhouly","year":"2020","journal-title":"Noncoding RNA Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.3892\/mmr.2019.10186","article-title":"MicroRNA-486-5p inhibits the growth of human hypertrophic scar fibroblasts by regulating Smad2 expression","volume":"19","author":"Shi","year":"2019","journal-title":"Mol Med Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"14131","DOI":"10.1038\/srep14131","article-title":"The anti-fibrotic effects and mechanisms of MicroRNA-486-5p in pulmonary fibrosis","volume":"5","author":"Ji","year":"2015","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1172\/JCI73579","article-title":"MicroRNA-486-dependent modulation of DOCK3\/PTEN\/AKT signaling pathways improves muscular dystrophy-associated symptoms","volume":"124","author":"Alexander","year":"2014","journal-title":"J Clin Invest"},{"key":"B37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/2044-5040-1-27","article-title":"Regulation of DMD pathology by an ankyrin-encoded miRNA","volume":"1","author":"Alexander","year":"2011","journal-title":"Skelet Muscle"},{"key":"B38","doi-asserted-by":"publisher","first-page":"681267","DOI":"10.3389\/fendo.2021.681267","article-title":"BMSC-derived exosomes inhibit dexamethasone-induced muscle atrophy via the miR-486-5p\/FoxO1 axis","volume":"12","author":"Li","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"100034","DOI":"10.1016\/j.mbplus.2020.100034","article-title":"Calreticulin is important for the development of renal fibrosis and dysfunction in diabetic nephropathy","volume":"8","author":"Lu","year":"2020","journal-title":"Matrix Biol Plus"},{"key":"B40","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/bph.12292","article-title":"NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db\/db mice","volume":"170","author":"Zhang","year":"2013","journal-title":"Br J Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"7600","DOI":"10.7150\/thno.47845","article-title":"Elevated IgE promotes cardiac fibrosis by suppressing miR-486a-5p","volume":"11","author":"Zhao","year":"2021","journal-title":"Theranostics"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1518022\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T06:57:53Z","timestamp":1738133873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1518022\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":41,"alternative-id":["10.3389\/fcvm.2025.1518022"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1518022","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"article-number":"1518022"}}